The disposition kinetics of gentamicin, an aminoglycoside antibiotic, were studied in seven tetraplegic and six paraplegic volunteers. The volume of distribution of gentamicin in 1/ kg of body weight varied in a statistically significant way from values of this parameter measured in normal subjects. The elimination of gentamicin in spinal man proceeded in a log-linear fashion accurately characterized by a one compartment open-model with a half-life of approximately 2 hours.
Introduction
In order to establish a rational approach to drug therapy in humans with spinal cord injury (SCI), it is necessary to acquire knowledge of drug metabolism and disposition kinetics in this population. There exists a substantial body of knowledge defining the pathophysiology of SCI in humans (Greenway et al., 1970; Claus-Walker et ai., 1977) but essentially no knowledge concerning the extent to which this pathophysiology affects drug disposition kinetics and metabolism in spinal man (Livshits and Yakovlev, 1972; SSIE, 1983) .
Gentamicin, an aminoglycoside antibiotic which has its greatest usefulness in the therapy of infections due to gram-negative bacilli, was chosen for pharmaco-kinetic analysis because of its wide use in the treatment of sepsis in spinal man. Knowledge of its disposition kinetics in SCI could be expected to have immediate clinical relevance. Low serum protein binding (Gordon et al., 1972) , negligible biotransformation (Regamey et al., 1973) , and disposition kinetics in the non spinal cord injured accurately characterized by one compartment-open model with first order elimination make it particularly attractive as a study drug (Gyselynck et al., 1971) .
This study was implemented to assess the affects of the pathophysiology of SCI on the disposition kinetics of gentamicin after a single intravenous dose.
Materials and methods
Thirteen male volunteer participants, 20 to 60 years of age, with traumatic spinal cord injury (SCI) receiving gentamicin prophylactically prior to elective urologic surgery and four healthy control subjects with an intact neuraxis were studied. Seven subjects were tetraplegic; six were paraplegic. All SCI subjects had complete physiological spinal cord transection of greater than 1 year duration. Written informed consent was obtained.
Criteria for exclusion from the study were:
l. Acute and/or febrile illness 2. 35 Vol % ;;:: hematocrit;;:: 50 Vol % 3. Cardiac or hepatic disease, renal insufficiency 4. Obesity (body weight> 15% excess as determined by actuarial tables) 5. Significant high frequency hearing loss None of the study participants had received or were receiving heparin, amino glycosides, carbenicillin, or any substances known to alter gentamicin metabolism or interfere with the analytical methodology. All participants pursued un restricted bedside activities during the sampling period. By studying each volunteer at the same time of day, the possible influence of normal or disrupted circadian rhythms (Claus-Walker et al., 1968) on gentamicin disposition kinetics was kept constant. Following placement of an indwelling heparinised scalp vein needle, a loading dose of gentamicin 1·5 mg/kg in 50 C.c. of diluent was infused over 30 minutes into a contralateral extremity. Samples of blood (5 ml) were drawn before beginning the gentamicin infusion, at the end of the infusion (zero time) and at 30, 60, 90, 120, 150, 180, 240, 300, 360, 420 and 480 minutes. The first 1·5 ml of each sample of blood was discarded to avoid possible inhibition of genta micin by the anticoagulant. Serum was separated and stored at -20°C until time of assay. Concentrations of gentamicin were determined by an enzyme immuno assay (O'Leary and Ratcliff, 1980) . All samples were run in duplicate with internal standards every 15 samples using a computer directed Gilford 3500 spectrophotometer at 340 nm and 30°C.
Following intravenous administration, the elimination kinetics of gentamicin are accurately characterized by a first order process and a one compartment-open model once equilibration has occurred at the end of the distribution phase. Kinetic parameters were derived from analysis of plots of the time-course of log serum gentamicin concentrations obtained from a weighted, iterative, nonlinear least-squares regression analysis (Hartley and Booker, 1965; Sawchuk et at., 1977) .
Testing for statistical significance of the difference between means and variance of kinetic parameters was carried out using a one-way analysis of variance (ANOV A). The difference between mean values of the serum concentrations of gentamicin vs time in quadriplegic and paraplegic subjects was evaluated for statistical significance using a two way split-plot ANOV A (Kirk, 1982) . Statistical analysis of data was carried out on a HP-85 microcomputer.
Results
Pharmacokinetic parameters for gentamicin in spinal man are displayed in Table  1 . The mean volume of distribution of gentamicin expressed in l(kg of body weight (gVd) was greater in spinal man (tetraplegic plus paraplegic subjects) as compared to an experimentally determined mean for normal volunteers. This difference was statistically significant (p < 0·05). The mean V d gentamicin in paraplegic subjects was greater than the mean Vd gentamicin in tetraplegic subjects or controls. Statistical significance for this observed difference was not demonstrated. The difference between the variances of gVd in tetraplegic subjects and in tetraplegic plus paraplegic subjects (spinal man) as compared to controls was statistically significant (Table 1) .
Two-variable correlation analysis of gV d with age of subject, level of injury and time elapsed since injury in all subjects, tetraplegic subjects, or paraplegic subjects demonstrated no statistically significant associations.
The mean total clearance of gentamicin (gCh) in ml(kg(min was greater in spinal man (tetraplegic plus paraplegic subjects) but this difference was not statistically significant as compared to an experimentally obtained mean for volunteers with an intact neuraxis. Difference between the variances of gCh in tetraplegic subjects, paraplegic subjects and controls was not statistic ally significant (Table 1) . Values for gCh in tetraplegic subjects and paraplegic subjects demonstrated wide intersubject variability.
Two-variable correlation analysis of gCh with age of subject, level of injury and time elapsed since injury in all subjects, tetraplegic subjects or paraplegic subjects demonstrated no statistically significant associations.
Analysis of plots of log serum gentamicin concentration vs time in tetraplegic subjects, paraplegic subjects, and tetraplegic plus paraplegic subjects showed similar elimination patterns after the distribution phase ( Figs. 1 and 2 ). Apparent differences between the means of serum gentamicin concentrations in tetra plegic and paraplegic subjects over time did not reach statistical significance (Fig. 2) . Extensive intersubject variability of pharmacokinetic parameters was observed in spinal cord injured subjects (Fig. 3) . The mean elimination half-life (t!) gentamicin for all study subjects and sub-groups did not differ significantly from the experimentally derived gentamicin elimination half-life (t!) in normal subjects which correlated well with literature values (Table 1 ).
Discussion
The pathophysiology of spinal cord injury (SCI) in the acute and chronic phase is extensive (Mathias et ai., Desmond, 1970) . Using gentamicin, an aminoglyco side antibiotic with a well studied pharmacokinetic profile, a protocol was designed to test the hypothesis that the pathophysiology of spinal cord injury alters the disposition kinetics of drugs. Analysis of the time-course of serum gentamicin levels in spinal man resulted in the calculation of values for pharmacokinetic parameters, which differed in a statistically significant way from experimentally derived values in normal subjects. Greater intersubject variability in pharmacokinetic parameters found in spinal man as compared to normal subjects. The greatest intersubject variability in pharmacokinetic parameters, contrary to expectations, was observed in the paraplegic subjects and many reflect the wider, more varied spectrum of physiologic disruption in this population and the resultant diversity of pathology to be expected in this the neurophysiologically least homogeneous of all study groups. Time (hours) Figure 2 . Decline of serum gentamicin levels in tetraplegic subjects (0) as compared to paraplegic subjects (.) following a 30-minute intravenous infusion of 1·5 mg/kg total body weight. The difference between the means of serum gentamicin levels at each time in tetraplegic subjects as compred to paraplegic subjects did not reach statistical significance.
The observed increase in the volume of distribution of gentamicin in l/kg of total body weight in spinal man as compared to normal subjects may be attributed to an absolute increase in extracellular fluid volume. This may be due to extensive erosion of muscle mass and other factors such as diminished peripheral venomotor tone contributing to the formation of subclinical oedema (Greenway et al., 1970; Bidart et al., 1971) . The ratio of body fat to total body weight increases both in spinal man and in normals with ageing. These changes are seen earlier and are of a greater magnitude in spinal man suggesting that these changes are dependent on the pathophysiology of SCI and not the physio logical changes which normally accompany ageing, chronic illness or extended immobilization (Greenway et al., 1970) .
The apparent volume of distribution of gentamicin is approximately 25 per cent of total body weight and corresponds to extracellular fluid volume (Ristuccia and Cunha, 1982) . No statistically significant difference in the volume of distribu tion of gentamicin in l/kg of total body weight (gV d) was observed in paraplegic subjects as compared to tetraplegic subjects. Since a significant distribution of gentamicin to adipose tissue has been demonstrated in normal subjects (Schwartz et al., 1978) , a greater gV d might be expected in tetraplegic subjects. Our data, however, contradict this and suggest that additional factors unique to the pathophysiology of SCI are operative. Among these are disturbances of cate- 
cholamine metabolism which result in changes in systemic vascular resistance in spinal man and serve to further distinguish paraplegic from tetraplegic sub jects (Naftchi et at., 1972). These alterations in catecholamine metabolism may be implicated as factors contributing to a redistribution of extracellular fluid volume measurable as a change in the apparent volume of distribution of gentamicin. In the aggregate, these disturbances of gross body composi tion, venomotor tone and systemic vascular resistance explain the change in volume of distribution which appears to distinguish spinal man from normal subjects. Total body clearance of gentamicin was greater in spinal cord injured subjects than in subjects with an intact neuraxis, however, a statistically significant difference between means was not demonstrated and our data allows us to conclude that an increase in the volume of distribution of gentamicin is the major determinant of gentamicin disposition in spinal man.
Following a single 30-minute intravenous infusion of gentamicin 1·5 mg/kg, serum levels remained above 1·0 J.1g/ml for less than 5 hours in more than 75 per cent of spinal cord injured subjects during the 8-hour study period. This observation suggests a significant potential for under-dosing this population with a resultant decrease in the therapeutic efficacy of gentamicin, if the clinician initiates therapy using algorithms or dosing regimens based on pharmacokinetic data obtained from the study of humans with an intact neuraxis.
The clinical significance of altered disposition kinetics of gentamicin in spinal man is unknown. The intersubject variability in gentamicin disposition and the uncertainty in predicting individual kinetic parameters emphasize the need to define individual pharmacokinetic profiles and individualize gentamicin dosing regimens (Sawchuck et al., 1977) . This need to individualize gentamicin dosing regimens in spinal man may ultimately be shown to include other drugs which share a pharmacokinetic profile with gentamicin.
The limited data are supportive of the hypothesis that spinal man constitutes a discreet population defined by characteristic pha r macokinetic parameters. Much work remains to be done, however, in order to understand and better characterize the clinical significance of altered gentamicin disposition kinetic in spinal cord injury.
